Leerink Partners Reiterates Buy Rating on Definium Therapeutics, Inc. (DFTX)
Leerink Partners maintains its buy rating on Definium Therapeutics, setting a $52 price target, a 23.43% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating for Definium Therapeutics, Inc. (DFTX) on June 22, 2026, with a price target of $52.
- Leerink Partners's $52 price target implies 23.43% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
- Shares of NasdaqGS:DFTX traded near $24.48 on Monday, with a market cap of approximately $2.67 billion and a beta of 2.378.
- Several insiders, including the CEO and CFO, purchased shares on June 22, 2026, reflecting confidence in the company's future.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Leerink Partners has reiterated its buy rating on Definium Therapeutics, Inc. (DFTX), maintaining a price target of $52. This affirmation came on June 22, 2026, as the stock traded close to $24.48 on the NasdaqGS.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Definium Therapeutics
BlackRock, Inc. opened a new position in Definium Therapeutics with 8,480,230 shares valued at about $160.3 million. Driehaus Capital Management LLC reduced its holdings by 625,313 shares, bringing its total to 5,911,889 shares worth approximately $111.7 million, representing a 9.6% decrease. Avoro Capital Advisors LLC also opened a new position, acquiring 5,000,000 shares valued at $94.5 million. Janus Henderson Group PLC and Deep Track Capital, LP each initiated positions with 3,556,041 and 3,000,000 shares, valued at $67.2 million and $56.7 million, respectively. Geode Capital Management, LLC followed suit with 2,495,399 shares worth around $47.2 million.
Definium Therapeutics, Inc. Stock Up 2.8%
On Monday, shares of NasdaqGS:DFTX traded near $24.48. Definium Therapeutics has a market cap of approximately $2.67 billion. The company is not currently profitable, resulting in no meaningful P/E ratio, but it has a forward P/E of -15.48. Its beta is 2.378, indicating higher volatility compared to the market. The stock's 52-week range is from $6.35 to $26.25. It has a 50-day moving average of $22.61 and a 200-day moving average of $16.28. The company's current ratio is 4.69, with a quick ratio of 4.60, and a debt-to-equity ratio of 14.62.
$DFTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Definium Therapeutics is expected to release its next earnings report on July 30, 2026. The company has not reported positive earnings, with an EPS of -$2.50. Its net margin is currently 0.0%, and return on equity stands at -94.7%.
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 22, 2026, several insiders bought shares of Definium Therapeutics. CEO Robert Barrow acquired 375,000 shares, while CFO Brandi Roberts and Chief Legal Officer Mark Sullivan each purchased 62,500 shares. Chief Medical Officer Daniel Karlin and Chief Commercial Officer Matthew Wiley also bought 100,000 and 62,500 shares, respectively. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 22, 2026, Leerink Partners maintained its buy rating on Definium Therapeutics with a $52 price target. Oppenheimer also maintained a buy rating, setting a target of $60. Canaccord Genuity reiterated its buy rating on June 16, 2026, with a target of $38. The consensus among analysts is a strong buy, with an average price target of $39.87 based on 15 opinions.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a biopharmaceutical company based in New York, NY, focusing on brain health disorders. The company, led by CEO Robert Barrow, employs 105 people. Its main products include DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism. Originally known as Mind Medicine (MindMed) Inc., it rebranded in January 2026.
Bottom Line
Definium Therapeutics is drawing attention with its innovative approach to treating brain health disorders. The reiterated buy rating from Leerink Partners and insider buying activity suggest confidence in the company's future prospects. Investors should note that these insights are based on past filings and analyst opinions, which may not reflect the current market conditions.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.